Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend ...

Shares of Charles River Laboratories International Inc. rallied 6.87% to $106.60 Monday, on what proved to be an all-around ...

We recently published a list of Traders Heavily Sold Down These 10 Stocks on Thursday. In this article, we are going to take ...

Charles River Laboratories International Inc. closed 60.67% short of its 52-week high of $254.15, which the company achieved ...

Charles River Labs faces a 60% loss due to reduced R&D spending, FDA's phase-out of animal testing, and increased competition ...

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2025 financial results on Wednesday, May 7th, before the market opens. A conference call has been scheduled to ...

The FDA's new policy to phase out animal testing caused a significant 28% drop in Charles River Labs' stock. Click to read ...

BofA analyst Michael Ryskin lowered the firm’s price target on Charles River (CRL) to $150 from $185 and keeps a Neutral rating on the shares.

On Thursday, shares in Charles River Laboratories, a leading contract research organizations that has stirred controversy over its use of non-human primates, plunged 28 percent after the FDA issued ...

Barclays lowered the firm’s price target on Charles River (CRL) to $145 from $160 and keeps an Equal Weight rating on the shares as part of a ...

This was the stock's third consecutive day of losses.